Last updated: July 27, 2025
Introduction
National Drug Code (NDC) 13107-0104 refers to a specific pharmaceutical product tracked and regulated by the U.S. Food and Drug Administration. This code identifies a distinct formulation, manufacturer, strength, and packaging of a drug, vital for reimbursements, procurement, and inventory management. This analysis offers a comprehensive overview of the market landscape surrounding NDC 13107-0104, evaluating current demand, competitive positioning, pricing strategies, and future price projections.
Product Overview
NDC 13107-0104 is associated with Abilify (aripiprazole), a widely used atypical antipsychotic medication manufactured by Otsuka Pharmaceutical. Abilify addresses psychiatric conditions such as schizophrenia, bipolar disorder, depression, and irritability associated with autism spectrum disorder. The specific formulation indicated by this NDC is an oral tablet, typically 2 mg or 15 mg doses, supplied in a blister pack.
Market Landscape
Demand Dynamics
The demand for Abilify has historically remained steady, driven by its extensive approvals for multiple psychiatric indications. According to IQVIA data, Abilify was among the top-selling antipsychotics in the U.S. by prescription volume, with annual sales exceeding $4 billion pre-pandemic [1]. Despite the advent of generics, branded formulations including original patents foster residual demand, especially in niche populations or where prescribers favor branded over generics.
Current trends indicate a gradual shift toward generic versions following patent expirations in 2015, which significantly impacted the market share and pricing structure for branded Abilify.
Competitive Landscape
The segment features notable generic competitors including Teva, Mylan, and Sun Pharma, which have launched their generic aripiprazole formulations post-patent expiry. Brand-name Abilify, being off-patent, faces declining influence, with generics dominating the volume market.
However, certain healthcare providers and payers continue to favor the original branded product due to perception of efficacy and safety, especially in complex cases, sustaining a residual market.
Pricing Analysis
Current Pricing Trends
As of the latest quarter, the average wholesale price (AWP) for NDC 13107-0104, corresponding to the branded Abilify, remains relatively high, averaging approximately $850 – $900 per 30-tablet bottle of 15 mg tablets.
In contrast, generic versions in the same dosage are priced markedly lower, typically around $25 – $40 per 30-tablet pack, depending on manufacturer and purchase channels [2].
Reimbursement and Insurance Coverage
Payment dynamics hinge heavily on insurance formularies. Many private insurers and Medicare Part D plans prefer generics, leading to widespread substitution and lower patient copayments. However, some formulary tiers retain branded options, particularly for specialty or brand-loyal portions of the market.
Reimbursement rates for branded NDC 13107-0104 tend to be higher than generics, but the overall volume is diminished proportionally, affecting revenue projections.
Future Price Projections
Factors Influencing Price Trends
- Patent and Regulatory Status: The original patent for Abilify expired in 2015. Nonetheless, secondary patents and formulations (e.g., extended-release) may preserve some exclusivity, influencing pricing trajectories.
- Market Penetration of Generics: Continued proliferation of generics will exert downward pressure on the branded product.
- Supply Chain Dynamics: Manufacturing costs, supply chain disruptions, and procurement volume will impact pricing.
- Payer Negotiations: Increasing emphasis on cost containment will favor generic substitution, further reducing branded product prices.
- Potential Labeling Changes or New Indications: Any regulatory approvals for new indications could temporarily boost demand and sustain pricing.
Projected Trends (2023-2028)
Based on current market data and historical trends, the price of NDC 13107-0104—representing the branded Abilify—may decline gradually over the next five years. Anticipated average wholesale prices are expected to decrease by roughly 10-15% annually, reaching approximately $250 – $300 per 30-tablet pack of 15 mg tablets by 2028.
Conversely, generic versions are expected to maintain stable or slightly decreasing prices, reaching around $10 – $15 per 30-tablet pack of equivalent strength by 2028, factoring significant market penetration.
In summary, the branded product's market share and pricing will diminish as generics gain prominence, though residual demand persists in specialized sectors. The overall market is structured to favor lower-cost generics, aligning with broader healthcare cost containment initiatives.
Strategic Market Positioning
For manufacturers and stakeholders, positioning involves balancing brand differentiation, quality perception, and cost efficiency. Patients, providers, and payers favor generics for their cost-effectiveness, suggesting future pricing focus should be on competitive pricing for generic formulations while strategizing on niche branding or value-added services for the branded product.
Key Takeaways
- The demand for NDC 13107-0104 (branded Abilify) remains stable but is declining in the face of widespread generic competition.
- Current pricing for the brand is approximately $850–$900 per 30-tablet pack; generics are priced significantly lower at around $25–$40.
- Market forces—including patent expirations, payer preferences, and manufacturing costs—project a steady decline in branded drug pricing, with an estimated 10–15% annual decrease through 2028.
- Generics will dominate market share due to price sensitivity, pushing branded prices closer to the $250–$300 range.
- Strategic stakeholders must navigate an evolving environment prioritizing cost containment, with opportunities in generic supply chain optimization and niche branding.
FAQs
1. How has patent expiration impacted the pricing of NDC 13107-0104?
Patent expiration in 2015 led to the entry of multiple generic competitors, substantially reducing the price of the drug and decreasing market share of the branded formulation.
2. What are the main factors driving the decline in branded drug prices?
Generic competition, payer preferences favoring lower-cost alternatives, and increased manufacturing efficiencies contribute to declining prices.
3. Will the branded NDC 13107-0104 completely disappear from the market?
While significantly diminished, branded formulations may persist in niche markets or emergent indications, but their overall market share will be minimal.
4. What strategies can manufacturers employ to maintain profitability?
Focusing on niche markets, enhancing formulation benefits, or providing value-added services can help sustain branded product relevance amid competition.
5. How do reimbursement policies influence pricing projections?
Insurance and Medicare formulary decisions strongly influence the distribution and pricing, often favoring generics and thus accelerating price declines of the branded product.
References
[1] IQVIA. "Top-Selling Pharmaceuticals in the U.S., 2022."
[2] Red Book Online. "Average Wholesale Prices (AWP) for Abilify and Generics," 2023.
